Group

Argentina has carved out a global niche in Biosimilar manufacturing. In 2026, Argentine firms are among the top exporters of high-quality, lower-cost biological versions of off-patent reference drugs to Europe and Southeast Asia.

Argentine labs utilize advanced "Disposable Bioreactor" technology (Single-Use Technology), which allows for smaller, more flexible manufacturing footprints. This agility has made Argentina a hub for "Contract Development and Manufacturing Organizations" (CDMOs), attracting significant venture capital from international investors looking for cost-effective, high-standard production sites.